Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Endocrine 2NET 1CNS 1

Conditions

Glioblastoma 12Brain Neoplasms 6Glioma 3Gliosarcoma 2Carcinoma, Non-Small-Cell Lung 2Thyroid Carcinoma, Anaplastic 1Small Cell Lung Carcinoma 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Melanoma 1HER2-positive Metastatic Breast Cancer 1Astrocytoma 1Adenoviridae Infections 1Adenocarcinoma 1

Interventions

trametinib 2dabrafenib 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1sargramostim 1cobimetinib 1cabozantinib 1atezolizumab 1aldesleukin 1Vemurafenib 1Trastuzumab 1Tamoxifen 1Semaxinib 1Radiotherapy 1Paclitaxel 1Gefitinib 1Doxorubicin 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × atezolizumab × CNS × Clear all
NCT04400474 2025-06-19

CABATEN

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
93 enrolled 17 charts
CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡